- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
|
|
410 |
|
|
|
|
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
|
Percutaneous surgery has a higher success |
are thought to have an influence in stone-free |
||
rate for simple stones than ESWL, but is obvi- |
rates.14 |
||
ously more invasive; nevertheless, PCNL has |
The Lower Pole Study Group15 reported a |
||
been shown to be both effective and safe13 with |
multicentre randomized trial of ESWL versus |
||
the inherent advantage of removal of a large |
PCNL for lower pole stones less than 3 cm in |
||
stone burden obviating the need for the patient |
size. It was found that overall stone-free rate was |
||
to pass the fragments generated by other |
far superior for PCNL compared to lithotripsy |
||
techniques. |
(95% vs. 37%) and for stones greater than 1 cm |
||
With flexible ureterorenoscopy, a successful |
the stone-free rate for ESWL was only 21%. This |
||
outcome of over 80% can be expected rising to |
group analyzed the various features of lower |
||
around 90% for repeat sessions when stones are |
pole anatomy, but did not find it to be of rele- |
||
treated with the combination of flexible uret- |
vance in the stone-free rate after ESWL. The |
||
eroscopy and laser given favorable anatomy and |
advent of flexible ureterorenoscopy has added a |
||
a modest stone burden. |
further option to the endourologist’s armamen- |
||
The following categories of stone require |
tarium, but there does remain a role for primary |
||
endoscopic surgery: Larger stones (>2 cm), |
lithotripsy stones of 1 cm or less as shown by a |
||
staghorn calculi, adverse anatomy (larger lower |
randomized prospective trial of ESWL versus |
||
pole stones, associated pelviureteric obstruc- |
ureteroscopy with results showing equivalent |
||
tion), certain stone compositions (cystine or |
success rates.16 |
||
calcium oxalate monohydrate).To this list should |
|
||
be added ESWL failures and certain patient fac- |
Horseshoe Kidneys and Stones |
||
tors including where ESWL is contraindicated |
|||
or not feasible (e.g., morbid obesity, bleeding |
The association between horseshoe kidneys and |
||
diatheses). |
|||
stones is well recognized. ESWL may be unsuc- |
|||
|
|
||
Staghorn Calculi |
cessful because of failure to target the stones |
||
with the kidney lying more anteriorly than usual |
|||
Guidelines indicate that these complex stones |
and there may be concern about drainage issues. |
||
Endoscopic surgery especially PCNL usually |
|||
should be treated by PCNL as ESWL monother- |
presents little difficulty although the skin to |
||
apy gives poor stone clearance.13 Careful plan- |
stone depth can be significantly larger than nor- |
||
ning of the approach enhanced in the modern |
mal. CT is particularly useful in planning the |
||
era by 3D CT reconstruction is helpful and mul- |
approach. |
||
tiple tracts may be required. An upper pole |
|
||
approach can improve the chances of stone |
Calyceal Diverticula Stones |
||
clearance with predominantly lower pole stag- |
|||
horn calculi which involve parallel calyces. The |
Stones in calyceal diverticula are very unlikely |
||
increased complication rate has been discussed |
|||
to be cleared by ESWL, but there is anecdotal |
|||
elsewhere. Supplementary ESWL for unreach- |
|||
evidence of resolution of symptoms. A percuta- |
|||
able fragments needs to be considered with |
|||
neous approach requires a precise placement of |
|||
sandwich therapy (PCNL, ESWL, PCNL) and |
|||
the tract into the diverticulum. Although this |
|||
second look nephroscopy as further options. |
|||
can be a challenge, stone removal is straightfor- |
|||
Refinements in PCNL techniques have however |
|||
ward when access is achieved. Attempts are then |
|||
further reduced the role of supplementary |
|||
made to gain access via the diverticulum into |
|||
ESWL.13 |
|||
|
|
the main collecting system to improve later |
|
|
|
drainage. Balloon dilatation has been proposed |
|
Lower Pole Stones |
to accomplish this17 and fulguration of the diver- |
||
|
|
ticulum has also been suggested to reduce the |
|
Lower pole anatomy has been thought to be rel- |
chances of recurrence. |
||
evant to the success or otherwise of ESWL for |
The alternative is to use the flexible uretero- |
||
lower pole stones. Such parameters as infundib- |
scope and the holmium laser.Finding the ostium |
||
ulo-pelvic angle, infundibular width and length |
to the diverticulum can be difficult but is greatly |
411
thE rolE of intErvEntional ManagEMEnt for Urinary tract calcUli
enhanced by careful screening in theater. The ostium may be incised with the laser to introduce the ureteroscope and allow treatment to the stone.
There is also a place for laparoscopic treatment and this may be useful if the parenchyma overlying the diverticulum is thin.
noncontrast CTs in the monitoring period. Clearly, if symptoms persist prolonged conservative therapy is not appropriate. It has been shown that in 10% of cases with asymptomatic stones irreversible renal loss of function is observed with serial renography.
Stones and PUJ Obstruction
The combination of stones in an obstructive system requires careful decision making. The question which requires consideration is whether stones are secondary to congenital obstruction or the cause of the obstruction. In addition the systemmaybebaggyratherthantrulyobstructed. MAG 3 renography can help in the workup and the presence of multiple small stones does suggest that the underlying problem may be one of primary obstruction. In the presence of drainage problems, ESWL is unlikely to be efficacious. Endoscopic approaches for PUJ obstruction which could be combined with endoscopic management of stone are described, such as pyelolysisandballoondilatation.Theroleof laparoscopic pyeloplasty is now established as standard treatment for PUJ obstruction and can be combined with stone removal to treat both problems definitively in one procedure.
Outcome of Treatment
of Ureteric Stones
Most small ureteric stones pass spontaneously.18 In a meta-analysis of over 2,700 cases, Hubner et al.19confirmed that the likelihood is inversely proportional to stones size with those <4 and >6 mm passing in 38% and 1.2% of cases,respectively. These stone passage figures are lower than those from historical series and may reflect the lower threshold for intervention in the modern era. The same study reported that stone site was a significant factor too, with passage rates of 12%, 22%, and 45% in the upper, mid, and distal ureter, respectively. Where a conservative approach is considered a follow-up strategy is required. The progress of radio-opaque stones can be monitored by serial plain x-rays. Those with radiolucent stones may end up with serial
Medical Treatment of Ureteric
Stones
Treatment of Ureteric Colic
Both nonsteroidal anti-inflammatory drugs (NSAIDs) and opiods are in common usage. Although the former class of drugs are usually the agent of first choice (e.g., diclofenac), caution is required due to possible gastrointestinal side effects and the adverse effect on renal function with long-term use or in those patients where kidney function is already impaired. NSAIDs are known to reduce ureteric contractility and have an impact on the prostaglandin pain pathway. If there are problems with potential side effects or lack of efficacy then opiods are given. In addition some advocate the use of spasmolytic agents.
Medical Expulsive Therapy (MET)
The role of medical therapy to enhance spontaneous passage has been the subject of significant interest in the past few years and it has been suggested that this practice is cost-effective over conservative therapy alone.20,21 A number of agents have been suggested including calcium channel blockers, corticosteroids, and alpha blockers. One randomized study reported increased rates of stone passage with a combination of corticosteroid and tamsulosin than combinations of other drugs with steroids including nifedipine.22 It seems entirely logical to consider medical expulsive therapy to aid passage of stone fragments generated by ESWL.
The most popular choice for MET in clinical use remains alpha-BLOCKADE and it is postulated that these drugs work because of the number of adrenergic receptors of the lower ureter. Patients do need to be warned about the side effects and it is important to note that this remains an offlicense use for this class of drugs.
|
|
412 |
|
|
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
Intervention for Ureteric Stones |
the ureter when ultrasound may be able to |
|
|
|
assist targeting. For giant ureteric stones there |
Absolute reasons for intervention include |
may be a role for laparoscopic surgery. The pos- |
|
pyonephrosis, persistent symptoms, bilateral |
sibility of utilizing percutaneous antegrade |
|
ureteric stones causing obstruction,and ureteric |
access particularly if there upper ureteric dila- |
|
stones causing obstruction to a solitary kidney. |
tation down to a large impacted stone also war- |
|
Relative indications include failure of progre- |
rants consideration. |
|
ssion and larger stone size. |
|
|
Pyonephrosis is an emergency situation and |
Stones in Pregnancy |
|
immediate drainage is required. There are advo- |
|
|
cates of emergency stenting, but this requires |
The combination of stone disease and preg- |
|
anesthesia and there may be concerns about the |
nancy presents a challenge in both diagnosis |
|
reliability of stent giving adequate decompres- |
and management. There are issues about expo- |
|
sion in all cases. Percutaneous nephrostomy |
sure to x-rays and imaging will be with ultra- |
|
drainage has the advantage of avoiding anes- |
sound or MRI will be required. The latter will |
|
thetics and consequent decompression of the |
not identify a stone but will indicate the level of |
|
system can still lead to spontaneous stone pas- |
any obstruction. The former will help in the |
|
sage when coaptation of the ureter is restored. |
detection of renal stones but may miss ureteric |
|
As there is access to the kidney the facility is |
calculi. If present hydronephrosis will be appar- |
|
there for contrast studies in follow-up. A recent |
ent, but this may be related to the pregnancy |
|
consensus report confirmed agreement in both |
rather than any primary urological problem. In |
|
urological and radiological circles that percuta- |
terms of management of proven stones, ESWL is |
|
neous drainage was preferable unless the patient |
contraindicated. Ureteroscopy may be consid- |
|
had clotting problems.23 |
ered, but this will be without the safety of radio- |
|
Regarding definitive treatment of the stone, |
logical screening. Temporizing measures such |
|
ESWL or ureteroscopy can be theoretically |
as nephrostomy drainage or stenting can be |
|
applied to calculi at any site particularly with |
considered until the pregnancy reaches term. |
|
the proliferation of flexible ureteroscopy. Patient |
There are disadvantages with both.Percutaneous |
|
or stone factors will determine which modality |
drains are uncomfortable and require a collec- |
|
is most suitable for a given stone scenario. There |
tion bag. They will need to be changed at |
|
is no evidence that stenting a patient with a ure- |
3-month intervals. Stents will accentuate blad- |
|
teric stone improves the outcome of ESWL. |
der problems and will require regular changes |
|
Previous guidelines suggest that ESWL is con- |
too and therefore the need for endoscopy and |
|
sidered the optimal treatment for upper ureteric |
anesthesia. |
|
stones less than 1 cm in size,18 whereas in the |
|
|
lower ureter, stone-free rates of ESWL and URS |
|
|
are equal and approach 100%.18,24 There is no |
Morbid Obesity |
|
evidence that stenting a patient with a ureteric |
|
|
stone improves the outcome of ESWL. Overall, a |
Patients in this category can present challenges |
|
recent meta-analysis showed that the stone-free |
in both radiological diagnosis and management. |
|
rate was higher, but with a higher complication |
Ultrasound is difficult in the obese and patients |
|
rate and longer hospital stay for URS compared |
may be too large to fit on the CT scanner. In |
|
to ESWL.25 There is however undoubtedly a role |
terms of treatment, ESWL may not be possible |
|
for ureteroscopy when ESWL does not work |
because the patient may be too heavy for the |
|
after a maximum of two treatments.26,27 |
table and the depth of the stone from the skin |
|
Stone size is a further issue with larger ure- |
may preclude targeting. The skin to stone dis- |
|
teric stones (>1 cm) being better treated endo- |
tance can make a percutaneous approach impos- |
|
scopically.18 Flexible ureteroscopy can be |
sible too or may require the use of longer |
|
invaluable in the upper ureter particularly if |
instruments. A patient’s obesity is less of an |
|
the ureter is dilated or tortuous. When stones |
issue when approaching a stone endoscopically, |
|
are radiolucent, there is no place for ESWL |
but the patient’s fitness for anesthesia and |
|
unless the stone is at the very top or bottom of |
comorbidities may be an issue. |